The six grants, which the NIH said are effective as of Dec. 26, but that ViroLogic had not previously disclosed, include:
$750,000 to develop an assay for measuring HIV-1 replication capacity;
$224,074 to build HIV phenotype/genotype database resources;
$299,768 to develop a cell-based assay to measure hepatitis C drug susceptibility;
$300,000 to develop assays for measuring the inhibition of HIV-1 enzymes;
$200,000 to develop assays for measuring the inhibition of virus entry; and
$841,731 to develop assays for measuring the inhibition of virus entry.
On Dec. 19, ViroLogic closed its $180-million acquisition of Aclara Biosciences. The companies announced the acquisition in June.
The companies combined Aclara's eTag platform with ViroLogic's laboratory, patient testing, and pharmaceutical drug-development business. ViroLogic, of
"Our combination of experience, infrastructure, technology and financial resources will provide the foundation to address the rapidly evolving field of targeted therapeutics and molecular diagnostics for infectious diseases and cancer," William Young, CEO and chairman of ViroLogic, said when the acquisition was sealed.
"We see the opportunity to apply our proven business model to the individualization of treatments in oncology. He will continue as CEO and chairman of the merged company
As GenomeWeb News reported in June, ViroLogic said it would buy Aclara in order to create a molecular-diagnostics company for oncology and infectious diseases.